147539-41-1

Usage

Uses

1. Used in Organic Chemical Synthesis:
1-Boc-4-Methylaminopiperidine is used as an organic chemical synthesis intermediate for the production of various pharmaceuticals and chemicals. Its unique structure allows for the creation of a wide range of compounds with diverse applications.
2. Used in Pharmaceutical Industry:
a) As a Key Intermediate for Antibacterial Agents:
1-Boc-4-Methylaminopiperidine is a derivative of 3-Methylaminopiperidine Dihydrochloride, which is a key intermediate for the synthesis of the antibacterial agent balofloxacin. This makes it an essential component in the development of new antibiotics to combat bacterial infections.
b) In the Development of New Drugs:
With its versatile chemical properties, 1-Boc-4-Methylaminopiperidine can be used in the pharmaceutical industry to develop new drugs with potential applications in various therapeutic areas, such as pain management, central nervous system disorders, and cardiovascular diseases.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13-7-5-9(12-4)6-8-13/h9,12H,5-8H2,1-4H3

Upstream product

• 593-51-1 methylamine hydrochloride 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 74-89-5 methylamine 
• 56553-60-7 sodium tris(acetoxy)borohydride 
• 107-06-2 1,2-dichloro-ethane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 7144-05-0 4-Aminomethylpiperidine 
• 546-68-9 titanium(IV) isopropylate 
• 191212-86-9 tert-butyl 4-(N-benzyl-N-methylamino)piperidine-1-carboxylate 
• 847039-05-8 4-(((benzyloxy)carbonyl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester 
• 301220-70-2 4-(N-(2-phenylethyl)amino)-1-(tert-butoxycarbonyl)piperidine 

Downstream Products

• 197727-57-4 4-(acetyl-methyl-amino)-piperidine-1-carboxylic acid tert-butyl ester 
• 618429-73-5 4-[(2S-benzyloxycarbonylamino-3,3-dimethylbutyryl)methylamino]piperidine-1-carboxylic acid tert-butyl ester 
• 847039-05-8 4-(((benzyloxy)carbonyl)(methyl)amino)piperidine-1-carboxylic acid tert-butyl ester 
• 301232-33-7 4-(N-(N-(4-nitrobenzyl)carbamoyl)-N-methylamino)-piperidine trifluoroacetate 
• 264904-01-0 2-(4-Amino-2,3,5,6-tetramethylanilino)-N-methyl-N-(4-piperidinyl)acetamide 
• 264905-31-9 2-(4-Amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide 
• 264904-14-5 2-(3-Amino-2,4,6-trimethylanilino)-N-methyl-N-(4-piperidinyl)acetamide 
• 264903-93-7 2-(4-Amino-2,3,5-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)propamide 
• 264903-95-9 2-(2-Amino-4,6-dimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide 
• 264903-96-0 2-(4-Amino-2,3,6-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide 
• 264903-97-1 2-(5-Amino-2-methoxyphenoxy)-N-methyl-N-(4-piperidinyl)acetamide 
• 264904-07-6 2-(4-Amino-2-chloro-3,5,6-trimethylphenoxy)-N-methyl-N-(4-piperidinyl)acetamide 
• 264904-10-1 2-(4-Amino-2,3,5,6-tetramethyl-N-methylanilino)-N-methyl-N-(4-piperidinyl)acetamide 
• 264904-13-4 2-(4-Dimethylamino-2,3,5,6-tetramethylanilino)-N-methyl-N-(4-piperidinyl)acetamide 

Relevant academic research and scientific papers

Synthesis of N,N-dialkyl-1-(2-alkylthiopyrimidin-4-yl)piperidin- 4-amines as potential heat shock protein inhibitors

A new efficient method for synthesizing promising heat shock protein inhibitors, N,N-dialkyl- 1-(2-alkylthiopyrimidin-4-yl)piperidin-4-amines, by the reaction of 2-alkyl-4-chlorothiouracils with 4-(N-alkyl-N-methylamino)piperidines was developed. 2-Alkyl-4-chlorothiouracils were synthesized by alkylation of 2-thiouracil with alkyl iodides and subsequent treatment of the intermediates with POCl3. 4-(N-Alkyl-N-methylamino)piperidines were prepared by reductive amination of 1-(tert-butoxycarbonyl)-4-piperidinone with methylamine followed by treatment of the intermediate with the appropriate aldehydes.

DEGRADATION OF ANDROGEN RECEPTOR (AR) BY CONJUGATION OF AR ANTAGONISTS WITH E3 LIGASE LIGAND AND METHODS OF USE

Provided herein are novel bifunctional compounds formed by conjugating AR antagonist moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 Ubiquitin ligase for degradation, and methods of preparation and uses thereof.

Design, synthesis and biological evaluation of anthranilamide derivatives as potent SMO inhibitors

A series of anthranilamide derivatives were designed and synthesized as novel smoothened (SMO) inhibitors based on the SMO inhibitor taladegib (LY2940680), which can also inhibit the SMO-D473H mutant, via a ring-opening strategy. The phthalazine core in LY2940680 was replaced with anthranilamide, which retained the inhibitory activity towards the hedgehog (Hh) signaling pathway as evidenced by a dual luciferase reporter gene assay. Compound 12a displayed the best inhibitory activity against the Hh signaling pathway with IC50 value of 34.09 nM, and exhibited better proliferation inhibitory activity towards the Daoy cell line (IC50 = 0.48 μM) than LY2940680 (IC50 = 0.79 μM).

Design, synthesis and biological evaluation of 7-chloro-9h-pyrimido[4,5-b]indole-based glycogen synthase kinase-3β inhibitors

Glycogen synthase kinase-3β (GSK-3β) represents a relevant drug target for the treatment of neurodegenerative pathologies including Alzheimer’s disease. We herein report on the optimization of a novel class of GSK-3β inhibitors based on the tofacitinib-derived screen hit 3-((3R,4R)-3-((7-chloro-9H-pyrimido[4,5-b]indol-4-yl)(methyl)amino)-4-methylpiperidin-1-yl)-3-oxopropanenitrile (1). We synthesized a series of 19 novel 7-chloro-9H-pyrimido[4,5-b]indole-based derivatives and studied their structure–activity relationships with focus on the cyanoacetyl piperidine moiety. We unveiled the crucial role of the nitrile group and its importance for the activity of this compound series. A successful rigidization approach afforded 3-(3aRS,7aSR)-(1-(7-chloro-9H-pyrimido[4,5-b]indol-4-yl)octahydro-6H-pyrrolo[2,3-c]pyridin-6-yl)-propanenitrile (24), which displayed an IC50 value of 130 nM on GSK-3β and was further characterized by its metabolic stability. Finally, we disclosed the putative binding modes of the most potent inhibitors within the ATP binding site of GSK-3β by 1 μs molecular dynamics simulations.

SMO (smoothened) inhibitor containing benzoylpiperidine structure and preparation and application methods thereof

The invention discloses a benzoylpiperidine derivative and preparation and application methods thereof. The benzoylpiperidine derivative is a compound containing N-methyl-N-(1-(2-aminobenzoyl)piperidine-4-yl)amide structure shown as the formula I. The invention also discloses a preparation method of the benzoylpiperidine derivative. The invention also discloses application of the benzoylpiperidinederivative to preparing SMO protein inhibitors as well as application of drug combinations containing the benzoylpiperidine derivative to preparing anti-tumor drugs.

Substituted heteroaryl compounds and compositions and uses thereof

The invention discloses a substituted ceteroary compound as well as a composition and an application thereof. The compound is a compound shown in a formula (I) or a stereisomer, a tautomer, a nitric oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The invention further discloses a pharmaceutical composition including the compound. The compound and the pharmaceutical composition are capable of adjusting the activity of the AK kinase and can be used for preventing, processing, treating and relieving the JAK-mediated disease or disorder.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heterocyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

IMIDAZOLECARBOXAMIDES AND THEIR USE AS FAAH INHIBITORS

A compound having a structure selected from the following: or a pharmaceutically acceptable salt thereof. The compound may be used as an inhibitor of fatty acid amide hydrolase.

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

There is provided a compound having Formula I:(I) wherein: R1 is aryl which is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy, or R1 is aryl which is substituted with a second aryl group or an aryloxy group, wherein the second aryl group or the aryloxy group is optionally substituted with one or more groups selected from hydroxyl, halogen and C1-4 alkoxy; R2 is C1-4 alkyl; R3 is selected from hydroxyl and OSO2CH3; R4 and R5 are independently selected from hydrogen, hydroxyl and halogen; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; wherein when R3 is hydroxyl and R4 and R5 are not hydroxyl, the optionally substituted aryl group, second aryl group or aryloxy group of R1 is substituted with one or more hydroxyl groups or C1-4 alkoxy groups, or wherein when R3 is hydroxyl, one of R4 and R5 is hydroxyl, provided that the compound is not N-(1-benzylpiperidin-4-yl)-4-(3,4-dihydroxyphenyl)-N-methyl-1H-imidazole-1-carboxamide hydrobromide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.